IMAging With Opto-acoustics to downgradE BI-RADS claSsificaTion Relative tO Other Diagnostic Methodologies (MAESTRO)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

217 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-27

Study Completion Date

2016-02-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Imagio breast imaging system, is an opto-acoustic (OA) imaging system designed to concurrently collect images in conjunction with diagnostic ultrasound ( co-registered OA and B-mode imaging). This medical device has CE-marking and is approved for use in Europe and other nations.

This is a post-market, non-randomized multi-center surveillance study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The PIONEER-01 Study of the Imagio Breast Imaging System

NCT01943916

Breast Cancer

COMPLETED NA

Clinical Evaluation of Opto-Acoustic Image Quality With the Gen 2 Imagio System

NCT05022602

Breast Cancer Stage

COMPLETED NA

Optoacoustic Images Versus Imagio® Ultrasound

NCT04030104

Breast Cancer

COMPLETED NA

CONFIDENCE Registry

NCT05084729

Breast Abnormality Diagnosis

COMPLETED

Imagio Feasibility Multi-Reader, Multi-Case Study

NCT03708393

Breast Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a post-market surveillance study that is prospective, controlled, multi-center, to evaluate if Imagio OA can downgrade BI-RADS ( Breast Imaging-Reporting and Data System) classification following CDU (Conventional Diagnostic Ultrasound) for the visualization and characterization of suspicious masses prior to core needle biopsy (CNB) or excision. Investigators will perform CDU to reach a diagnosis and decision to biopsy. Imagio OA will not be used as the reason to perform or to defer a CNB (Core Needle Biopsy) or excision.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Imagio IUS gray-scale ultrasound

Imagio gray-scale ultrasound

Group Type ACTIVE_COMPARATOR

Imagio IUS

Intervention Type DEVICE

Imagio diagnostic gray-scale ultrasound

Imagio OA/US

Intervention Type DEVICE

Diagnostic opto-acoustic +gray-scale ultrasound

Imagio OA/US

Imagio OA/US (opto-acoustic+gray-scale ultrasound)

Group Type OTHER

Imagio IUS

Intervention Type DEVICE

Imagio diagnostic gray-scale ultrasound

Imagio OA/US

Intervention Type DEVICE

Diagnostic opto-acoustic +gray-scale ultrasound

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Imagio IUS

Imagio diagnostic gray-scale ultrasound

Intervention Type DEVICE

Imagio OA/US

Diagnostic opto-acoustic +gray-scale ultrasound

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

gray-scale ultrasound Imagio opto-acoustic + gray-scale ultrasound

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female
* 18 years of age or older
* Have an undiagnosed suspicious finding which may include more than one solid or complex cystic suspicious mass, classified by CDU as BI-RADS 4a or 4b within 3 weeks of their baseline Imagio Scan

Exclusion Criteria

* Have a condition or impediment that could interfere with the intended field of view (within one probe length or 4 cm of the mass), (i.e., breast implants within the previous 12 months, or tattoos)
* Pregnant or lactating
* Patient has received chemotherapy for any type of cancer within 90 days from date of screening CDU

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No